{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:02Z","timestamp":1791327422268,"version":"4.3.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>Secondary immunodeficiency (SID) and hypogammaglobulinemia have been reported to be related to an increase in various infections and poor outcome, and it is important to evaluate immunoglobulin replacement therapy (IgRT) at an appropriate timing. The objective of this study is to evaluate the safety and efficacy of glycine-stabilized 20% subcutaneous immunoglobulin (Ig20Gly) in Japanese patients with hematological malignancies accompanied by SID. The patients who were administered Ig20Gly at least once at Tottori Prefectural Central Hospital were enrolled in this study. Information about the patient characteristics, hematological parameters, presence or absence of histories of infection before and after IgRT, and all adverse events during and after Ig20Gly administration was collected from clinical records. We retrospectively evaluated the efficacy and safety of Ig20Gly in 27 patients with a median age of 68 years. The incidences of infection during the 1 year prior to the initiation of IgRT, the period of l-proline-stabilized 20% subcutaneous immunoglobulin administration, and the period of Ig20Gly administration were 3.67\/patient-years, 1.81\/patient-years, and 1.32\/patient-years, respectively. No systemic adverse events were observed during the period of Ig20Gly administration, but a total of 69 cases of local adverse events were observed in 18 patients (66.7%). All adverse events were grade 1 and mild. Ig20Gly reduced the incidence of infection in patients with SID, and few systemic and only mild local adverse events were observed, suggesting a high level of safety.<\/jats:p>","DOI":"10.1097\/md.0000000000045145","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:16Z","timestamp":1762211056000},"page":"e45145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence from Japan in patients with hematological malignancies and secondary hypogammaglobulinemia treated with 20% subcutaneous immunoglobulin, Ig20Gly: A retrospective cohort study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-9814","authenticated-orcid":false,"given":"Yoshinori","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Hosoda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Omura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management.","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"103896","DOI":"10.1016\/j.critrevonc.2022.103896","article-title":"Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.","volume":"181","author":"Shah","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-Cell therapy.","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.19203","article-title":"A single-institution pre-post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients.","volume":"204","author":"Suga","year":"2024","journal-title":"Br J Haematol"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bmt.2014.28","article-title":"Risk factors for hypogammaglobulinemia after allo-SCT.","volume":"49","author":"Arai","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R9-20260915","first-page":"5187","article-title":"Medical Oncology (AIO) of the German Cancer Society (DKG). Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.","volume":"30","author":"Link","year":"2022","journal-title":"Support Care Cancer"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"e930241","DOI":"10.12659\/MSM.930241","article-title":"Secondary immunodeficiency and hypogammaglobulinemia with IgG Levels of <5\u2009g\/L in patients with multiple myeloma: a retrospective study between 2012 and 2020 at a university hospital in China.","volume":"27","author":"Ye","year":"2021","journal-title":"Med Sci Monit"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies.","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"e15362","DOI":"10.1111\/ped.15362","article-title":"Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.","volume":"64","author":"Imai","year":"2022","journal-title":"Pediatr Int"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial.","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/16078454.2022.2051863","article-title":"Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab.","volume":"27","author":"Hirata","year":"2022","journal-title":"Hematology"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/curroncol30010022","article-title":"A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency.","volume":"30","author":"Visentin","year":"2022","journal-title":"Curr Oncol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/imt-2019-0057","article-title":"Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.","volume":"11","author":"Suez","year":"2019","journal-title":"Immunotherapy"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13223-022-00709-8","article-title":"Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: canadian real-world study.","volume":"18","author":"Keith","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"107365","DOI":"10.1016\/j.leukres.2023.107365","article-title":"Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: regional perspectives.","volume":"133","author":"Ar","year":"2023","journal-title":"Leuk Res"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis.","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/10428194.2022.2131424","article-title":"Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.","volume":"64","author":"Sim","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"1098326","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review.","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees.","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: systematic review and meta-analysis.","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia.","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"R26-20260915","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study.","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus.","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur J Haematol"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/imj.14082","article-title":"Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey.","volume":"49","author":"Wong","year":"2019","journal-title":"Intern Med J"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12325-011-0036-y","article-title":"Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.","volume":"28","author":"Jolles","year":"2011","journal-title":"Adv Ther"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s10875-018-0560-5","article-title":"Long-term efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency in Japan, Europe, and the United States: a review of 7 phase 3 trials.","volume":"38","author":"Jolles","year":"2018","journal-title":"J Clin Immunol"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10875-016-0327-9","article-title":"Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20 % in patients with primary immunodeficiency diseases in North America.","volume":"36","author":"Suez","year":"2016","journal-title":"J Clin Immunol"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12866","article-title":"Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a phase 2\/3 study in Europe in patients with primary immunodeficiencies.","volume":"187","author":"Borte","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"ltae001","DOI":"10.1093\/immadv\/ltae001","article-title":"Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.","volume":"4","author":"Kanegane","year":"2024","journal-title":"Immunother Adv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:29Z","timestamp":1789498949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":33,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045145","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}